On June 10, Shougang LanzaTech fell 5.15% in regular trading, trading at 29.76 HKD/share, with trading volume of approximately 25.99 million HKD.

The decline is driven by continued profit-taking as short-term gains accumulated rapidly since the company's IPO on June 3 at 14.6 HKD/share. Despite the pullback, cumulative post-listing gains still exceed 100%. The stock had rebounded on June 8-9 following the announcement that its globally pioneering CO₂ biosynthesis ethanol project entered trial production, but selling pressure resumed as investors locked in gains.

On the fundamental side, the company has explicitly stated it cannot achieve net profit breakeven in the short term. Additionally, the IPO international placement received only 0.95x subscription, reflecting cautious institutional sentiment that contrasts sharply with the 1,421x retail oversubscription. Valuation digestion pressure persists following the rapid post-listing doubling.

Shougang LanzaTech, established in 2011, is the first company in the CCUS industry to achieve commercialization and scale production of low-carbon products using verified synthetic biology technology, currently operating four production facilities across China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)